Alector Names Neil Berkley as CFO to Strengthen Financial Foundation

  //business-finance.news-articles.net/content/202 .. y-as-cfo-to-strengthen-financial-foundation.html
  Published in Business and Finance on Friday, December 12th 2025 at 16:54 GMT by Seeking Alpha
      Locale: CANADA

Alector Names Neil Berkley as Chief Financial Officer – What It Means for the Neuro‑Immunology Company

In a move that underscores its continued focus on building a robust financial foundation, Alector (NASDAQ: ALCT) announced on March 12, 2024 that Neil Berkley will step into the role of Chief Financial Officer (CFO). The appointment follows a series of strategic initiatives aimed at accelerating the development of the company’s portfolio of neuro‑immunology therapeutics and securing the capital structure needed to support the next phase of clinical activity. Below we break down the key details of the hire, the background of the new CFO, and what this development signals for Alector’s shareholders and pipeline.

A Quick Primer on Alector

Founded in 2013, Alector is a biotechnology firm dedicated to treating neurodegenerative disorders—chiefly Alzheimer’s disease (AD) and Parkinson’s disease (PD)—through novel approaches that harness the body’s innate immune system. The company’s flagship programs are AL‑108 (a small‑molecule immunotherapy for AD) and AL‑201 (a gene‑therapy‑based product for PD), both of which have entered critical clinical milestones. In addition to its pipeline, Alector has cultivated partnerships with academic institutions and other biotechs to expand its platform capabilities.

Financially, Alector has been navigating a typical biotech trajectory: periodic fundraising rounds, modest operating income, and a strong focus on cash burn management. Investors have watched the company’s stock closely, given its high valuation—reaching an all‑time high of $24.30 in early 2023—yet the shares have been volatile as clinical data have trended.

Who Is Neil Berkley?

Neil Berkley is an accomplished finance executive with a proven track record in the life‑sciences sector. He brings over 25 years of experience spanning investment banking, corporate finance, and operations within the biotechnology and pharmaceutical industries. Prior to joining Alector, Berkley held senior roles at:

• Pfizer Inc. – Managing financial strategy for multiple oncology and immunology units, where he was responsible for budgeting, forecasting, and M&A activity.
• Genentech (a Roche company) – Overseeing capital allocation and working capital optimization during a period of rapid product pipeline expansion.
• Biogen Inc. – Leading the finance team during the launch of a major multiple sclerosis therapy, which required close coordination with regulatory agencies and global markets.

Berkley’s expertise is especially relevant to Alector’s growth trajectory. He has repeatedly demonstrated a capacity to raise capital through equity and debt offerings, streamline financial reporting, and create value‑creation pathways for high‑growth biotech firms. Notably, his experience in navigating the regulatory requirements of the U.S. Securities and Exchange Commission (SEC) and managing investor relations will be invaluable as Alector continues to engage with its shareholder base.

The CFO Transition

Alector’s former CFO, David L. Gosselin, stepped down at the end of February 2024 to pursue other opportunities. Gosselin had led the company’s finance operations since 2020, overseeing the transition from early‑stage funding rounds to more complex capital‑raising efforts that included a $75 million secondary offering in late 2023. Under his tenure, the company maintained a disciplined cash burn profile while scaling its R&D operations.

Neil Berkley’s appointment is effective March 15, 2024, according to the company’s press release. In a statement, Alector CEO Kris M. Miller said:
> “Neil brings a depth of experience in the life sciences that aligns perfectly with our mission. His expertise in capital strategy, financial reporting, and operational efficiency will be critical as we progress our lead programs and expand our global footprint.”

Berkley will report directly to Miller and will assume responsibility for:

• Financial planning & analysis (budgeting, forecasting, cash‑flow management);
• Investor relations (SEC filings, quarterly earnings, and strategic communications);
• Capital structure management (equity/debt issuance, shareholder communications);
• Operational oversight of accounting and compliance functions.

He is also expected to work closely with the Board’s Audit & Risk Committee and the Compensation Committee to align remuneration structures with long‑term value creation for shareholders.

Why This Hire Matters for Alector

1. Capital‑Efficiency and Growth
   Alector’s next phase of clinical development, especially the Phase 3 push for AL‑108, demands substantial funding. A seasoned CFO like Berkley will help the company design a balanced capital structure that can support ongoing trials while maintaining a healthy runway.

2. Strategic M&A and Partnerships
   The company has been exploring strategic collaborations to bolster its pipeline—most notably a recent joint‑venture agreement with a European biopharma to co‑develop a next‑generation immunotherapy. Berkley’s M&A background will be crucial in negotiating and integrating such deals.

3. Regulatory and Investor Confidence
   Accurate and timely SEC filings, coupled with transparent financial communication, are essential to maintaining investor confidence, particularly during periods of clinical uncertainty. Berkley’s history of successful public‑market engagements positions Alector to manage these expectations adeptly.

4. Global Expansion
   Alector plans to expand into the Asian and European markets. This will require a CFO who can navigate multi‑currency reporting, local compliance, and cross‑border financing—all areas where Berkley’s international experience shines.

A Glance at Alector’s Financial Landscape

• Cash Position: As of December 2023, Alector reported $210 million in cash and equivalents, sufficient to fund operations through the end of 2025 assuming current burn rates.
• Projected Cash Burn: The company’s operating expenses are projected to increase by ~30 % year‑over‑year as clinical programs accelerate.
• Capital Raise Plans: Alector is evaluating a $100 million equity infusion or a $50 million senior secured debt facility, contingent on market conditions and the progress of AL‑108.

These numbers underscore the importance of a CFO who can balance growth financing with prudence.

Looking Ahead

Neil Berkley’s arrival signals Alector’s commitment to professionalizing its financial operations as it steps into a new chapter of accelerated clinical development. Investors will likely monitor how quickly the company can raise the necessary capital, the pace of its program milestones, and how well it manages cash burn—all areas where Berkley’s leadership should have a visible impact.

For Alector’s stakeholders, the appointment suggests a higher degree of financial discipline and a more robust strategy for navigating the inherent uncertainties of drug development. As the company moves toward its Phase 3 clinical trial launch in Q4 2024 for AL‑108 and continues to develop AL‑201, the CFO’s role will be pivotal in translating scientific progress into shareholder value.

Source: Seeking Alpha – “Alector Appoints Neil Berkley as Chief Financial Officer” (March 12, 2024). Additional context gleaned from Alector’s SEC filings and the company’s investor relations website.